Arcturus Therapeutics Holdings Inc. announced interim results from its ongoing Phase 2 clinical trial of ARCT-032, an investigational inhaled mRNA therapy for individuals with cystic fibrosis. In the study's second cohort, six adults with Class I CF received daily inhaled doses of 10 mg ARCT-032 over 28 days. The treatment was generally safe and well tolerated, with treatment-related adverse events similar to those observed in a previous single-dose Phase 1 study. One serious adverse event occurred after the dosing period, but the Data Monitoring Committee found no convincing evidence of a relationship to ARCT-032 and approved the study to continue. Early findings suggest a trend towards reduction in mucus plugs and volume, as seen in AI-enhanced lung imaging, and exploratory lung function data analysis. An expanded third cohort is ongoing to assess dose escalation and safety at 15 mg. Arcturus plans to initiate a 12-week safety and preliminary efficacy study in up to 20 cystic fibrosis participants in the first half of 2026. Results from the current interim analysis have already been presented.